Recently, cancer treatment was revolutionized by the use of immune checkpoint blockade. Through the use of inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), cytotoxic T cells can be activated to destroy tumor cells. The first immune checkpoint inhibitor to display high antitumor activity was the monoclonal antibody ipilimumab, and even though it has improved the outcome of different types of cancer, several immune-related adverse events (irAEs) have been reported associated to its use.